Trial Profile
A Study to Evaluate the Safety and Pharmacokinetics of Quizartinib in Combination With Standard Induction Therapy and Consolidation Therapy in Chinese Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 27 Jul 2022 Status changed from recruiting to completed.
- 07 Apr 2022 Planned End Date changed from 28 Feb 2022 to 30 Sep 2022.
- 07 Apr 2022 Planned primary completion date changed from 28 Feb 2022 to 30 Jun 2022.